Aspirin works by permanently disabling an enzyme called cyclooxygenase, which the body uses to produce a family of signaling molecules involved in pain, inflammation, blood clotting, and fever. That single act of sabotage ripples through multiple systems at once, which is why one small tablet can simultaneously ease a headache, reduce a fever, and protect against a heart attack. But the details of how aspirin achieves each of those effects, why the dose matters so much, and what can go wrong along the way are far more interesting than the textbook summary suggests.
How Aspirin Disables the Enzyme
Aspirin’s chemical name is acetylsalicylic acid, and the “acetyl” part is the key. When aspirin reaches the cyclooxygenase (COX) enzyme, it hands off its acetyl group to a specific amino acid, serine-530, sitting inside the enzyme’s active site. This is a permanent, covalent bond, not the temporary, reversible attachment that most other painkillers make. Once that acetyl group is stuck to serine-530, the channel through which the enzyme’s natural substrate, arachidonic acid, normally enters becomes physically blocked.1PubMed Central. Residual cyclooxygenase activity of aspirin-acetylated COX-2 forms 15 R-prostaglandins that inhibit platelet aggregation The enzyme is effectively dead. It cannot be repaired or reactivated; the cell has to build a new copy from scratch.2PubMed Central. Crystal Structure of Aspirin-Acetylated Human Cyclooxygenase-2: Insight into the Formation of Products with Reversed Stereochemistry
This irreversibility is what makes aspirin unique among common painkillers. Ibuprofen and naproxen also target COX, but they bind loosely and let go once the drug leaves the bloodstream. Aspirin’s covalent attachment means its effects outlast the drug itself. Aspirin is cleared from your blood in a matter of hours, but the enzymes it disabled stay disabled until the cell replaces them, a process that can take days in some tissues.
Two Versions of the Same Enzyme
The body makes two forms of cyclooxygenase, COX-1 and COX-2, and they do different jobs. COX-1 is present all the time in most tissues. It helps maintain the stomach lining, supports kidney function, and drives platelet activation for blood clotting. COX-2, by contrast, is produced mainly in response to injury or infection and ramps up the production of prostaglandins that cause pain, swelling, and fever. Aspirin disables both, but it is roughly 150 to 200 times more potent against COX-1 than COX-2.3PubMed. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis
That potency gap is the reason aspirin’s dose changes what it does. A low dose, like the 75–100 mg “baby aspirin” used for heart protection, is enough to wipe out COX-1 in platelets almost completely while leaving COX-2 largely untouched elsewhere in the body. Anti-inflammatory doses used for conditions like rheumatoid arthritis are much larger, often 3,000 mg or more per day, because silencing COX-2 at sites of inflammation requires far higher concentrations.3PubMed. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis
Why Low-Dose Aspirin Targets Platelets So Precisely
Platelets are uniquely vulnerable to aspirin for a simple biological reason: they have no nucleus. Most cells in the body can respond to COX being destroyed by reading the gene and building a fresh enzyme within hours. Platelets cannot do this. Once aspirin acetylates their COX-1, that platelet’s ability to produce thromboxane Aâ‚‚, the powerful clot-promoting signal, is gone for the rest of its roughly ten-day lifespan.4European Heart Journal. Low-Dose Aspirin for the Prevention of Atherosclerotic Cardiovascular Disease
Meanwhile, the endothelial cells lining blood vessels also use COX to make prostacyclin (also called PGIâ‚‚), a molecule that does the opposite of thromboxane: it relaxes vessels and discourages clotting. Because endothelial cells have nuclei, they resynthesize any acetylated COX-2 within a few hours, well before the next daily aspirin dose arrives. Low-dose aspirin’s short half-life in the blood means it hits platelets hard in the portal circulation but clears before it can suppress prostacyclin production in a sustained way.4European Heart Journal. Low-Dose Aspirin for the Prevention of Atherosclerotic Cardiovascular Disease Controlled-release formulations exploit this even further: one study showed that maximal suppression of platelet thromboxane Aâ‚‚ was sustained during long-term dosing while systemic prostacyclin synthesis remained largely preserved.5PubMed. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin
This selective suppression of thromboxane while preserving prostacyclin is the pharmacological basis for using low-dose aspirin in cardiovascular prevention. Aspirin is recommended for the secondary prevention of heart attacks, strokes, and other atherosclerotic events, and in some cases for primary prevention in high-risk individuals.6PubMed Central. New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism At higher single doses (325 or 650 mg), the selectivity collapses: both thromboxane and prostacyclin are suppressed by more than 90%, and the inhibition persists for about a week.7Journal of the American College of Cardiology. Platelet function and biosynthesis of prostacyclin and thromboxane A2in whole blood after aspirin administration in human subjects
How Aspirin Eases Pain
When tissue is damaged, cells release arachidonic acid, and COX enzymes convert it into prostaglandins Eâ‚‚ and Iâ‚‚. These prostaglandins do not cause pain directly; instead, they sensitize the nerve endings (nociceptors) at the injury site so that stimuli that would normally feel mild become painful.8PubMed Central. Peripheral analgesia: mechanism of the analgesic action of aspirin-like drugs and opiate-antagonists This heightened sensitivity, hyperalgesia, is a core part of inflammatory pain. By blocking prostaglandin synthesis at the site of injury, aspirin dials the nerve endings back down to something closer to their normal threshold.9PubMed. Differential analgesic effects of aspirin-like drugs
In animal models of arthritis, aspirin reduced mechanically-evoked nerve firing by about 40% and spontaneous nerve activity by about 30% within 15 minutes of injection.10PubMed Central. Effects of paracetamol and aspirin on neural activity of joint mechanonociceptors in adjuvant arthritis That is a meaningful but incomplete effect, which matches everyday experience: aspirin takes the edge off most aches but does not eliminate serious pain the way stronger analgesics can.
How Aspirin Reduces Fever
Fever works through the same prostaglandin pathway, just in a different location. When the immune system detects an infection, signals reach the hypothalamus, the brain’s thermostat, and trigger local production of prostaglandin Eâ‚‚. The rise in PGEâ‚‚ shifts the hypothalamic set point upward, and the body responds by conserving and generating heat.11The American Journal of Medicine. Antipyretics: mechanisms of action and clinical use in fever suppression Aspirin lowers fever by blocking the COX-driven production of PGEâ‚‚ in the hypothalamus, effectively pulling that set point back down. Research in animal models has suggested aspirin may also suppress an additional pathway in the hypothalamus involving hydroxyl radicals, providing an extra avenue of antipyretic action beyond straightforward prostaglandin inhibition.12Journal of Pharmacological Sciences. Aspirin May Exert Its Antipyresis by Inhibiting the N-Methyl-D-aspartate Receptor-Dependent Hydroxyl Radical Pathways in the Hypothalamus
Why Aspirin Hurts the Stomach
The same COX-1 enzyme that aspirin disables in platelets also maintains the protective lining of the stomach. Prostaglandins produced by gastric COX-1 stimulate mucus secretion and increase blood flow through the stomach wall, both of which protect the tissue from its own acid. When aspirin suppresses that prostaglandin production, the defenses weaken. Aspirin also acts as a direct irritant to the gastric mucosa, initially increasing local blood flow as an inflammatory response. But because COX-1 is simultaneously inhibited, the subsequent reduction in blood flow prevents the stomach from buffering and diluting acid that back-diffuses from the lumen into the tissue.13Gastroenterology. Aspirin-Induced Gastric Mucosal Injury: Lessons Learned From Animal Models The result is a double hit: a weakened barrier and reduced ability to cope with acid exposure. This is why even low-dose aspirin, taken daily over months or years, can cause stomach erosions and ulcers.
When Aspirin Does Not Work as Expected
A fraction of people taking daily aspirin for heart protection do not get the expected antiplatelet effect, a phenomenon loosely called “aspirin resistance.” The term is a bit misleading, because the aspirin molecule itself almost always does what it is supposed to at the enzyme level. The failure usually happens elsewhere. The single biggest contributor appears to be poor adherence: people who forget doses or take them inconsistently.14Pharmacology & Therapeutics. Mechanisms of aspirin resistance
Beyond compliance, biological factors play a role. People with chronic inflammatory conditions like atherosclerosis may have high platelet turnover, meaning fresh platelets with intact COX-1 enter the bloodstream faster than a once-daily dose can keep up with. Some individuals have platelets that are inherently more reactive even before aspirin is started, which shows up on laboratory tests as apparent “resistance” even though aspirin is doing its biochemical job normally.15PubMed. Aspirin ‘resistance’: role of pre-existent platelet reactivity and correlation between tests Other proposed contributors include drug interactions, genetic variations in COX or platelet surface proteins, and diabetes.16PubMed. The concept of aspirin “resistance”: mechanisms and clinical relevance Researchers have also identified an anion pump on platelets that can actively expel aspirin from the cell before it reaches the enzyme, a mechanism that could reduce efficacy in some people.14Pharmacology & Therapeutics. Mechanisms of aspirin resistance
Ibuprofen and the Timing Problem
One of the more practically important wrinkles in aspirin pharmacology is its interaction with ibuprofen. Both drugs target the same COX-1 active site, but ibuprofen binds reversibly and aspirin binds irreversibly. If you take ibuprofen before aspirin, ibuprofen can sit in the active site and physically block aspirin from reaching serine-530. The aspirin passes through the bloodstream without ever acetylating COX-1 on the platelet, and its antiplatelet effect is lost.17PubMed. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin A single daily dose of ibuprofen given before aspirin, or multiple daily doses throughout the day, both blocked aspirin’s ability to suppress platelet aggregation in clinical testing.
Selective COX-2 inhibitors (coxibs) can also theoretically compete at the active site, but in practice, therapeutic doses of drugs like rofecoxib and etoricoxib did not meaningfully interfere with aspirin’s antiplatelet effect, likely because their preference for COX-2 leaves COX-1 relatively open for aspirin to acetylate.18PubMed Central. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin For people on daily low-dose aspirin for heart protection who also need pain relief, the practical advice from clinicians is often to take the aspirin first and wait before taking ibuprofen, or to use a different painkiller.
Aspirin-Exacerbated Respiratory Disease
About 7% of adults with asthma and a larger fraction of those with nasal polyps have a condition where aspirin (and other COX inhibitors) triggers severe respiratory symptoms: worsening asthma, nasal congestion, and sometimes anaphylaxis-like reactions. This is aspirin-exacerbated respiratory disease, or AERD. The mechanism has nothing to do with a classic allergic reaction. Instead, it stems from a pre-existing overproduction of cysteinyl leukotrienes, inflammatory molecules produced by an enzyme pathway (5-lipoxygenase) that runs parallel to the COX pathway.19PubMed Central. Factors driving the aspirin exacerbated respiratory disease phenotype
In people with AERD, cells overexpress 5-lipoxygenase and leukotriene Câ‚„ synthase, pumping out high baseline levels of cysteinyl leukotrienes. When aspirin shuts down the COX pathway, arachidonic acid that would normally be metabolized by COX gets shunted toward the leukotriene pathway instead, producing a sudden surge. Making things worse, platelets that have adhered to white blood cells contribute more than half of the total leukotriene Câ‚„ synthase activity in circulating granulocytes, amplifying the leukotriene burst through a cooperative handoff between the two cell types.20PubMed Central. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes The reaction is to the biochemical shift, not to aspirin as a foreign molecule.
Aspirin and Children
Aspirin is generally avoided in children and teenagers with viral illnesses because of the association with Reye syndrome, a rare but potentially fatal condition involving acute liver failure and brain swelling. Reye syndrome typically follows a viral infection like influenza or chickenpox, with a symptom-free gap of a few days before the rapid onset of vomiting, confusion, and liver dysfunction.21PubMed. Aspirin and Reye syndrome: a review of the evidence The exact mechanism linking aspirin to the syndrome is not fully established, but the prevailing explanation involves a widespread disturbance in mitochondrial function, particularly in the liver.
Laboratory research has shown that aspirin at doses within the physiological range can dramatically amplify the immune system’s response to viral-like stimulation, causing T-lymphocytes to proliferate up to threefold more than they would without aspirin. This hyperproliferative effect was reversed by adding prostaglandin Eâ‚‚ back to the system, suggesting that aspirin’s suppression of prostaglandins removes a natural brake on the immune response.22Prostaglandins, Leukotrienes and Medicine. Reye’s syndrome and aspirin use: A possible imuunological relationship Since warnings about aspirin use in children became widespread in the 1980s, Reye syndrome cases have dropped sharply.
Aspirin-Triggered Lipoxins and Anti-Inflammatory Signals
One of the more surprising findings about aspirin’s mechanism is that acetylated COX-2 does not become completely inert. In cells that express COX-2, the acetylated enzyme can still metabolize arachidonic acid, but it produces a different set of products, notably 15-epi-lipoxin Aâ‚„, commonly called aspirin-triggered lipoxin (ATL).1PubMed Central. Residual cyclooxygenase activity of aspirin-acetylated COX-2 forms 15 R-prostaglandins that inhibit platelet aggregation Lipoxins are part of the body’s resolution machinery, the system that actively switches off inflammation once the threat is handled. ATL signals through a receptor on immune cells that dampens further inflammatory activity. Research has found that plasma levels of aspirin-triggered lipoxin are lower in patients with peripheral artery disease than in healthy individuals, and that both ATL and a related molecule, resolvin E1, can block the migration of smooth muscle cells that contributes to artery thickening.23PubMed Central. Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis
This discovery reframed aspirin from a drug that simply blocks inflammation to one that actively nudges the body toward resolving it. The distinction matters because chronic, unresolved inflammation is now understood to drive many diseases, from atherosclerosis to cancer.
Colorectal Cancer Prevention
A large body of epidemiological and clinical data suggests that long-term aspirin use reduces the risk of colorectal cancer. The mechanisms behind this are still debated, but COX-2 inhibition is probably part of the story: many colorectal tumors overexpress COX-2, and the prostaglandin PGEâ‚‚ it produces promotes cell proliferation, suppresses immune surveillance, and encourages new blood vessel formation that feeds tumor growth.24PubMed Central. Mechanisms of Colorectal Cancer Prevention by Aspirin-A Literature Review and Perspective on the Role of COX-Dependent and -Independent Pathways
But COX inhibition alone does not explain everything. Aspirin also acetylates COX-2 to generate aspirin-triggered lipoxins, which have demonstrated anti-tumor properties of their own. COX-1 inhibition at low doses may also contribute, since platelets can release growth factors that help circulating tumor cells survive and establish new colonies. Beyond COX entirely, aspirin has been shown to affect several other signaling pathways in cancer cells, including modification of the transcription factor NF-κB and induction of programmed cell death.25Best Practice & Research Clinical Gastroenterology. Pharmacology and cellular/molecular mechanisms of action of aspirin and Non-aspirin NSAIDs in colorectal cancer The honest state of the science is that aspirin probably prevents colorectal cancer through several mechanisms working in parallel, and researchers have not yet established which is primary.
Low-Dose Aspirin in Pregnancy
Preeclampsia, a dangerous complication of pregnancy involving high blood pressure and organ damage, is linked to an imbalance between thromboxane Aâ‚‚ and prostacyclin in the placental blood vessels. The same imbalance that aspirin corrects in cardiovascular disease, too much clot-promoting thromboxane relative to vessel-relaxing prostacyclin, appears to contribute to the abnormal placental blood flow seen in preeclampsia.26American Journal of Obstetrics and Gynecology. Low-dose aspirin in the prevention of preeclampsia and fetal growth retardation: Rationale, mechanisms, and clinical trials Low-dose aspirin, typically started before 16 weeks of gestation in women at high risk, aims to selectively suppress platelet thromboxane while sparing endothelial prostacyclin, exactly the same dose-dependent selectivity that makes low-dose aspirin useful for heart protection.
What Happens After You Swallow It
Aspirin is absorbed quickly from the stomach and upper small intestine. Once in the bloodstream, it begins acetylating COX enzymes almost immediately, but its own survival is short. Enzymes called carboxylesterases in the blood and liver rapidly break aspirin down into salicylic acid, its main metabolite.27PubMed. Clinical pharmacokinetics of aspirin Salicylic acid has some anti-inflammatory activity of its own, but it cannot acetylate COX; it works through different, weaker mechanisms. For anti-inflammatory therapy, plasma salicylate levels need to be maintained within a fairly narrow window, high enough to be effective but low enough to avoid toxicity, symptoms of which include ringing in the ears, nausea, and in severe cases metabolic disturbances.
The rapid conversion of aspirin to salicylic acid is paradoxically what makes low-dose aspirin so effective for platelet inhibition. Aspirin has only a brief window in the blood to acetylate COX, but because platelets pass through the portal circulation on the way from the gut, they encounter aspirin at its highest concentration before the liver breaks most of it down. It is a pharmacokinetic coincidence that works out beautifully for cardiovascular dosing.
Efforts to Build a Safer Version
Because aspirin’s gastrointestinal side effects flow directly from the same COX-1 inhibition that provides its benefits, researchers have tried to decouple the two. One approach is NO-aspirin, a hybrid molecule that links aspirin to a nitric oxide-releasing chemical group. Nitric oxide independently promotes stomach blood flow and mucus production, compensating for the protection lost when COX-1 is inhibited.28Digestive and Liver Disease. NO-aspirin: mechanism of action and gastrointestinal safety In laboratory testing, a more advanced version called NOSH-aspirin, which releases both nitric oxide and hydrogen sulfide, reduced prostaglandin levels in stomach tissue just as aspirin did but caused no stomach ulcers, while conventional aspirin caused significant bleeding at the same prostaglandin-lowering dose.29PubMed Central. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications These hybrids are not yet in routine clinical use, but they illustrate how deeply researchers understand the mechanism: well enough to try re-engineering the drug from the ground up while keeping its core COX-inhibiting action intact.
Aspirin’s Roots in Plant Defense
The story of aspirin begins long before pharmacology. Salicylic acid, the molecule aspirin is built from, is a major defense hormone in plants. When a plant is attacked by a pathogen, salicylic acid levels surge, activating a cascade of immune-like responses that help the plant resist infection and even “prime” neighboring tissues against future attack.30PubMed Central. Salicylic acid in plant immunity and beyond Willow bark, one of the richest natural sources of salicylates, was used as a remedy for pain and fever for thousands of years before anyone understood why it worked. In 1897, Felix Hoffmann at Bayer synthesized the acetylated form of salicylic acid, creating what we now call aspirin. It was not until 1971 that John Vane showed that aspirin worked by inhibiting prostaglandin synthesis, a discovery that earned him the Nobel Prize.31Thrombosis Research. The mechanism of action of aspirin The gap between using the drug and understanding it was about 3,500 years, making aspirin one of the longest-running success stories in medicine running entirely on empirical evidence before anyone knew the mechanism.